Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

SHOCKING: Adaptimmune rapeutics | Mind Blowing Facts

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022

Upgrades

Benzinga · Nov 9, 2022

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

Benzinga · Nov 8, 2022

12 Health Care Stocks Moving In Friday's Intraday Session

Benzinga · Jun 3, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Adaptimmune Therapeutics's Return On Capital Employed Insights

Benzinga Pro data, Adaptimmune Therapeutics (NASDAQ:ADAP) reported Q1 sales of $3.58 million. Earnings fell to a loss of $50.27 million, resulting in a 29.36% decrease from last quarter.

Benzinga · Jun 3, 2022

A Preview Of Adaptimmune Therapeutics's Earnings

Adaptimmune Therapeutics (NASDAQ:ADAP) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Adaptimmune Therapeutics will report an earnings per share (EPS) of $-0.22.

Benzinga · May 6, 2022

Adaptimmune Therapeutics Q1 2022 Earnings Conference Call On May 9, 2022 At 08:00 AM ET

Adaptimmune Therapeutics (NASDAQ:ADAP) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.

Benzinga · May 4, 2022

Looking Into Adaptimmune Therapeutics's Return On Capital Employed

According to Benzinga Pro data, during Q4, Adaptimmune Therapeutics (NASDAQ:ADAP) posted sales of $1.42 million. Earnings were up 8.36%, but Adaptimmune Therapeutics still reported an overall loss of $38.86 million.

Benzinga · Mar 16, 2022

Read news from The Economist, FT, and more,
with one subscription

A Preview Of Adaptimmune Therapeutics's Earnings

Adaptimmune Therapeutics (NASDAQ:ADAP) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement. Analysts estimate that Adaptimmune Therapeutics will report an earnings per share (EPS) of $0.14.

Benzinga · Mar 11, 2022

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.